These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2450893)

  • 1. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME
    J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor.
    Zhong RK; Kozii R; Ball ED
    Br J Haematol; 1995 Oct; 91(2):269-74. PubMed ID: 8547061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement.
    Venneker GT; Vodegel RM; Okada N; Westerhof W; Bos JD; Asghar SS
    Immunobiology; 1998 Feb; 198(4):476-84. PubMed ID: 9562871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
    Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall.
    Niculescu F; Rus HG; Vlaicu R
    Immunol Lett; 1990 Oct; 26(1):17-23. PubMed ID: 1703512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
    Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
    J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement.
    Wang MW; Wright LJ; Sims MJ; White DJ
    Scand J Immunol; 1991 Dec; 34(6):771-8. PubMed ID: 1721235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
    Horta MF; Ramalho-Pinto FJ
    J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.
    Bjørge L; Junnikkala S; Kristoffersen EK; Hakulinen J; Matre R; Meri S
    Br J Cancer; 1997; 75(9):1247-55. PubMed ID: 9155042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
    Seya T; Hara T; Matsumoto M; Sugita Y; Akedo H
    J Exp Med; 1990 Dec; 172(6):1673-80. PubMed ID: 2258699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Seya T; Kojima A; Hara T; Hazeki K; Sugita Y; Akedo H
    Immunobiology; 1991 Sep; 183(1-2):115-24. PubMed ID: 1718846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.